Technical Analysis for OLMA - Olema Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | -9.21% | |
| 200 DMA Resistance | Bearish | -9.21% | |
| 50 DMA Resistance | Bearish | -9.21% |
| Alert | Time |
|---|---|
| Down 1 ATR | 2 days ago |
| 60 Minute Opening Range Breakdown | 2 days ago |
| Down 5% | 2 days ago |
| Down 3% | 2 days ago |
| Expansion Pivot Sell Entry | 2 days ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/05/2024
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Olema is headquartered in San Francisco.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Breast Cancer Treatment Of Breast Cancer Epidermal Growth Factor Receptor Hormones Targeted Therapy Her2 Her2/Neu Estrogen Antiestrogens Estrogen Receptor Selective Estrogen Receptor Degraders Fulvestrant
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Breast Cancer Treatment Of Breast Cancer Epidermal Growth Factor Receptor Hormones Targeted Therapy Her2 Her2/Neu Estrogen Antiestrogens Estrogen Receptor Selective Estrogen Receptor Degraders Fulvestrant
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 16.775 |
| 52 Week Low | 8.51 |
| Average Volume | 450,058 |
| 200-Day Moving Average | 12.12 |
| 50-Day Moving Average | 12.00 |
| 20-Day Moving Average | 11.72 |
| 10-Day Moving Average | 11.63 |
| Average True Range | 0.84 |
| RSI (14) | 25.93 |
| ADX | 15.15 |
| +DI | 18.15 |
| -DI | 35.50 |
| Chandelier Exit (Long, 3 ATRs) | 10.99 |
| Chandelier Exit (Short, 3 ATRs) | 11.63 |
| Upper Bollinger Bands | 13.32 |
| Lower Bollinger Band | 10.12 |
| Percent B (%b) | -0.3 |
| BandWidth | 27.23 |
| MACD Line | -0.35 |
| MACD Signal Line | -0.09 |
| MACD Histogram | -0.2518 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 10.79 | ||||
| Resistance 3 (R3) | 10.95 | 10.57 | 10.52 | ||
| Resistance 2 (R2) | 10.57 | 10.16 | 10.49 | 10.43 | |
| Resistance 1 (R1) | 9.87 | 9.90 | 9.68 | 9.71 | 10.34 |
| Pivot Point | 9.49 | 9.49 | 9.40 | 9.41 | 9.49 |
| Support 1 (S1) | 8.79 | 9.08 | 8.60 | 8.63 | 8.00 |
| Support 2 (S2) | 8.41 | 8.82 | 8.33 | 7.91 | |
| Support 3 (S3) | 7.71 | 8.41 | 7.82 | ||
| Support 4 (S4) | 7.55 |
